These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37353375)

  • 1. Toxicity Management of Systemic Kidney Cancer Therapies.
    Qin Q; Nein E; Flaten A; Zhang T
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):993-1003. PubMed ID: 37353375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.
    Cohen RB; Oudard S
    Invest New Drugs; 2012 Oct; 30(5):2066-79. PubMed ID: 22327313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the treatment of metastatic renal cell carcinoma.
    Abe H; Kamai T
    Int J Urol; 2013 Oct; 20(10):944-55. PubMed ID: 23692504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicities of targeted agents in advanced renal cell carcinoma.
    Patel P; Srinivas S
    Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
    Jaimes EA
    Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.
    Zengin ZB; Salgia NJ; Chehrazi-Raffle A; Meza L; Malhotra J; Pal SK
    Cancer J; 2020; 26(5):432-440. PubMed ID: 32947311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF inhibitors in renal cell carcinoma.
    Vachhani P; George S
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):1016-1028. PubMed ID: 28212363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
    Appleby L; Morrissey S; Bellmunt J; Rosenberg J
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of available treatment options for renal cell carcinoma.
    Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
    Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
    Gao X; McDermott DF
    Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney cancer: current and novel treatment options.
    Jonasch E
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):679-81. PubMed ID: 25995429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
    Huang JJ; Hsieh JJ
    Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
    Hutson TE; Sonpavde G; Galsky MD
    Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
    Parikh M; Lara PN
    Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.